The Subtype-Selective Nicotinic Acetylcholine Receptor Agonist SIB-1553A Improves Both Attention and Memory Components of a Spatial Working Memory Task in Chronic Low Dose 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Monkeys
Authors:
- J. S. SchneiderJSJ. S. Schneider
- J. P. TinkerJTJ. P. Tinker
- F. MenzaghiFMF. Menzaghi
- G. K. LloydGLG. K. Lloyd
- 1 July 2003
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 306 (1) , 401-406
Abstract
Monkeys that receive chronic low dose (CLD) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration develop deficits in spatial delayed-response task performance. The present study examined the extent to which SIB-1553A [(±)-4-{[2-(1-methyl-2-pyrrolidinyl)ethyl]thio}phenol hydrochloride], a novel neuronal nicotinic acetylcholine receptor (nAChR) agonist with selectivity for β4 subunit-containing nAChRs, could counteract this cognitive deficit produced by CLD MPTP exposure. Prior to MPTP treatment, monkeys displayed a delay-dependent decrement in performance on a variable delayed response task. CLD MPTP treatment caused a shift to a delay-independent pattern of responding on this task, such that short-delay trials were performed as poorly as long-delay trials. At lower doses (e.g., 0.025 mg/kg), SIB-1553A significantly improved performance on short-delay trials but only at 24 h after drug administration. At higher doses (e.g., 0.50 mg/kg), SIB-1553A significantly improved performance on both short- and long-delay trials at both 20 min and 24 h after drug administration. When tested 24 h after drug administration, monkeys performed long-delay trials with greater accuracy than they did under normal (pre-MPTP) conditions. These results suggest that at lower doses, SIB-1553A may be more effective in improving attentional deficits associated with CLD MPTP exposure, whereas at higher doses, SIB-1553A may effectively improve both attentional and memory performance.Keywords
This publication has 30 references indexed in Scilit:
- DIFFERENT EFFECTS OF DOPAMINERGIC AND ANTICHOLINERGIC THERAPIES ON COGNITIVE AND MOTOR FUNCTION IN PARKINSON'S DISEASEBrain, 1992
- l-Dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunctionPsychopharmacology, 1992
- COGNITIVE IMPAIRMENT IN EARLY, UNTREATED PARKINSON'S DISEASE AND ITS RELATIONSHIP TO MOTOR DISABILITYBrain, 1991
- Beneficial effects of nicotine administered prior to a delayed matching-to-sample task in young and aged monkeysNeurobiology of Aging, 1991
- Impaired extra-dimensional shift performance in medicated and unmedicated Parkinson's disease: Evidence for a specific attentional dysfunctionNeuropsychologia, 1989
- ‘Subcorttcal dementia’: The neuropsychological evidenceNeuroscience, 1988
- ‘FRONTAL’ COGNITIVE FUNCTION IN PATIENTS WITH PARKINSON'S DISEASE ‘ON’AND ‘OFF’ LEVODOPABrain, 1988
- Selective Delayed Response Deficits in Parkinson's and Alzheimer's DiseaseArchives of Neurology, 1986
- The effect of Parkinson's disease on the ability to maintain a mental set.Journal of Neurology, Neurosurgery & Psychiatry, 1985
- Visuospatial Impairment in Parkinson's DiseaseArchives of Neurology, 1984